Evidaxia

JCA Pulse › Ongoing JCA

Ongoing JCA

Relacorilant (Lifyorli): EU joint clinical assessment

Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

  1. Regulatory review
  2. CHMP opinion
  3. EU authorised
  4. JCA report published

Overview

Company
Corcept Therapeutics
Therapy area
Solid tumours · Gynaecological
Indication
Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
Product type
Chemical, Orphan designation
EMA validation
30 Oct 2025
JCA assessor
INFARMED, Portugal
Co-assessor
SBU, Sweden
Regulatory status
CHMP positive 18 Sep 2026 (with nab-paclitaxel). EC decision pending at last check.
Latest
Awaiting EU authorisation; national HTA not started.
Pivotal evidence
ROSELLA (phase 3) + phase 2 (RCT)
01

Scope

The PICO forecast

JCA Pulse forecasts 2 PICOs for Relacorilant, with 2 candidate comparators. See the populations, comparators and likely outcomes the assessment is set to cover.

Unlock the PICO forecastFree with email
02

Evidence

Fit against the likely scope

Relacorilant’s pivotal evidence (ROSELLA) is randomised. Pro scores how well it fits each likely PICO and flags where assessors may push back.

Included in Pro
03

Comparisons

Trials and indirect comparisons

Pro maps every trial likely in the Relacorilant dossier and projects the indirect comparison each comparator will need.

Included in Pro
04

Countries

National translator and outlook

Portugal and Sweden lead the joint assessment. Pro explains what the JCA means for the national route in each of 31 markets.

See JCA Pulse ProIncluded in Pro

Next milestones

  • 18 Sep 2026CHMP positive opinion · EU · source

Sources

Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.

From Evidaxia

Also in Solid tumours